

Review of: "Efficacy of Potassium Competitive Acid Blockers (P-CABs) versus Proton Pump Inhibitors (PPIs) in the First and Second Line Eradication Regimens for *Helicobacter pylori* in Egyptian Patients"

Oscar Teramoto-Matsubara¹

¹ Centro Médico ABC

Potential competing interests: No potential competing interests to declare.

Dear Sir,

It is interesting research regarding an important aspect of the questionable *Helicobacter pylori* treatment. The first and most important aspect is its prevalence and the high rate of antibiotic resistance reported all around the world. As a result, several guides and consensus have been postulated to avoid treatment regimens that could be disastrous.

For the same reason, there are several questions that could be of interest in order to understand your research:

- a) It is not clear what the indication was to diagnose the presence of the *Helicobacter pylori* infection.
- b) What symptoms did the patients have before the treatment? Did you perform an endoscopy on all or some of the patients?
- c) The eradication was confirmed only by the fecal test? How many of the infected patients had symptoms before and after the treatment? You mention "symptom relief" in your table, what do you mean by it?
- d) Do you have any guidelines to choose your first or second line of treatment? Did all who entered into groups c and d have the same first line of treatment (Clarithromycin 500 mg BID, Amoxicillin 1 gm BID, and Esomeprazole 20 mg BID)?
- e) Do you have any exact statistics regarding the resistance rate of clarithromycin in your community? If so, why do you continue using it?

Hope you could help us understand some of these questions that may be obvious to you.

Sincerely,